EUVIMEDEUVIMED entdecken
Crossref

Pathologic assessment Reveals limited efficacy of immunotherapy in recurrent high-grade salivary gland carcinomas: A clinicopathologic and genomic study

Zhen Zhu, Junhui Yuan, Xu Zhang, Liyuan Dai, Wei Du, Xiaoli Liu

Journal of Cranio-Maxillofacial Surgery · 2026

DOI: 10.1016/j.jcms.2025.11.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cranio-Maxillofacial Surgery, 2026. Verfasst von Zhen Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. Hauptthemen laut MEDLINE: Salivary Gland Neoplasms, Neoplasm Recurrence, Local, Immunotherapy. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrent high-grade salivary gland carcinomas (SGCs) have limited treatment options, and immunotherapy's role remains unclear. This study evaluated radiologic and pathologic responses to immunotherapy in resectable recurrent high-grade SGCs. We retrospectively analyzed 108 patients from a tertiary center: 41 received neoadjuvant immunotherapy, while 67 underwent upfront surgery. Radiologic response (RECIST 1.1) and pathologic response (immune-related criteria) were discordant-34.1 % showed partial radiologic responses, but only 9.8 % achieved partial pathologic responses, with no complete responses. PD-L1 amplification correlated with response (25 % vs. 8.1 % in non-responders, p = 0.042), whereas B2M loss (29.3 % post-treatment, p = 0.032) and TP53/PIK3CA co-mutations (37.8 % in non-responders) were linked to resistance. Survival did not differ between groups (3-year event-free survival: 19.5 % vs. 23.9 %, p = 0.447; overall survival: 26.8 % vs. 31.3 %, p = 0.593). These findings highlight immunotherapy's limited pathologic efficacy in recurrent high-grade SGCs, with response rates lower on pathologic than radiologic assessment. PD-L1 and B2M alterations underscore the need for biomarker-driven strategies. This study provides a foundation for improving outcomes in this aggressive disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salivary Gland NeoplasmsNeoplasm Recurrence, LocalImmunotherapyHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultNeoplasm GradingNeoadjuvant TherapyTreatment OutcomeB7-H1 AntigenGenomicsAged, 80 and over

Stichwörter der Autor:innen

Immune checkpoint inhibitorsPD-L1Pathologic responseSalivary gland cancerimmunotherapy

Substanzen

B7-H1 Antigen

Autor:innen und Institutionen

  • Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
  • Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
  • Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. Electronic address: duweitj@126.com.
  • Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. Electronic address: 1007928588@qq.com.

Zitieren

APA

Zhu, Z., Yuan, J., Zhang, X., Dai, L., Du, W., & Liu, X. (2026). Pathologic assessment Reveals limited efficacy of immunotherapy in recurrent high-grade salivary gland carcinomas: A clinicopathologic and genomic study. Journal of Cranio-Maxillofacial Surgery. https://doi.org/10.1016/j.jcms.2025.11.018

Vancouver

Zhu Z, Yuan J, Zhang X, Dai L, Du W, Liu X. Pathologic assessment Reveals limited efficacy of immunotherapy in recurrent high-grade salivary gland carcinomas: A clinicopathologic and genomic study. Journal of Cranio-Maxillofacial Surgery. 2026. doi:10.1016/j.jcms.2025.11.018

BibTeX
@article{Zhu2026,
  author = {Zhu, Zhen and Yuan, Junhui and Zhang, Xu and Dai, Liyuan and Du, Wei and Liu, Xiaoli},
  title = {Pathologic assessment Reveals limited efficacy of immunotherapy in recurrent high-grade salivary gland carcinomas: A clinicopathologic and genomic study},
  journal = {Journal of Cranio-Maxillofacial Surgery},
  year = {2026},
  doi = {10.1016/j.jcms.2025.11.018}
}
Kostenlos starten →